| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4c0d3089587d794d8227df84abe09c4 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate |
2011-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fa63c6786dea7d5325835a509bda8f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1386680bcb993c84a1a18c962b7851a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cadf90bc26180295769146f926ea7e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fd6b9f1bd183b76befc8ff1592d0935 |
| publicationDate |
2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-700629-A |
| titleOfInvention |
Combination, kit and method of reducing intraocular pressure |
| abstract |
The present disclosure is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist of formula (I) and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The disclosire is particularly directed to a combination of latanoprost marketed under the brand Xalatan TM and Compound A. |
| priorityDate |
2010-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |